“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD.

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that ...

SunRISe-4 targets MIBC patients ineligible for or refusing cisplatin-based chemotherapy, addressing an unmet medical need. The trial evaluates TAR-200 plus cetrelimab and cetrelimab monotherapy, ...

"Overall, TAR-200 is being tested with the aim of changing the therapeutic paradigm of patients with an early bladder cancer diagnosis, including non–muscle-invasive disease and muscle-invasive ...

A 4-gene signature (ATM, RB1, FANCC, ERCC2) correlates with tumor absence post-neoadjuvant chemotherapy in muscle-invasive bladder cancer. The biomarker is more effective at predicting disease ...

"If the documentation supported the use of modifier –22, it should be appended," write Jonathan Rubenstein, MD, and Mark Painter. "When determining which code you should use, you must consider your ...

F-flotufolastat shows a 69% detection rate for recurrent prostate cancer in patients with PSA levels above 0.2 ng/mL post-prostatectomy. The agent demonstrates a 50% detection rate for PSAs below 0.2 ...

Aquablation offers personalized treatment plans using real-time ultrasound and AI, distinguishing it from traditional TURP procedures. The heat-free nature of Aquablation reduces post-operative ...

"We wanted to look at the importance of genetic testing in patients with GU cancer and the impact that it has on their treatment decision-making, and the pathways that we put them on," says Mouneeb ...

"Donor-advised funds are a fast-growing charitable giving vehicle in the US because they are one of the easiest and most tax-advantageous ways to give to charity," writes Jeff Witz, CFP. “[This way, I ...

SBRT shows promise in achieving progression-free survival in metastatic RCC without systemic therapy, despite limited high-level data. The absence of phase 3 trials leaves a gap in comparing SBRT ...

“We are pleased that a first patient has been imaged in the CA-NINE trial, which supports potential label expansion for TLX250-CDx into recurrent, metastatic disease,” says David N. Cade.